drugset / Trial / NCT05506956
Post-transplant Flotetuzumab for AML
Phase 1
Completed
3 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MacroGenics · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
Timeline
- Start
- 2022-10-20
- Primary completion
- 2024-06-18
- Completion
- 2024-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flotetuzumab | Monoclonal antibody | 0.3 ug/kg | Other |
| Subject | Flotetuzumab | Monoclonal antibody | 0.5 ug/kg | Other |